Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Añadir filtros








Intervalo de año
1.
Braz. j. med. biol. res ; 45(12): 1240-1243, Dec. 2012. ilus
Artículo en Inglés | LILACS | ID: lil-659636

RESUMEN

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used extensively to control inflammatory pain. Several peripheral antinociceptive mechanisms have been described, such as opioid system and NO/cGMP/KATP pathway activation. There is evidence that the cannabinoid system can also contribute to the in vivo pharmacological effects of ibuprofen and indomethacin. However, there is no evidence of the involvement of the endocannabinoid system in the peripheral antinociception induced by NSAIDs. Thus, the aim of this study was to investigate the participation of the endocannabinoid system in the peripheral antinociceptive effect of NSAIDs. All experiments were performed on male Wistar rats (160-200 g; N = 4 per group). Hyperalgesia was induced by a subcutaneous intraplantar (ipl) injection of prostaglandin E2 (PGE2, 2 μg/paw) in the rat’s hindpaw and measured by the paw pressure test 3 h after injection. The weight in grams required to elicit a nociceptive response, paw flexion, was determined as the nociceptive threshold. The hyperalgesia was calculated as the difference between the measurements made before and after PGE2, which induced hyperalgesia (mean = 83.3 ± 4.505 g). AM-251 (80 μg/paw) and AM-630 (100 μg/paw) were used as CB1 and CB2 cannabinoid receptor antagonists, respectively. Ipl injection of 40 μg dipyrone (mean = 5.825 ± 2.842 g), 20 μg diclofenac (mean = 4.825 ± 3.850 g) and 40 μg indomethacin (mean = 6.650 ± 3.611 g) elicited a local peripheral antinociceptive effect. This effect was not antagonized by ipl CB1 cannabinoid antagonist to dipyrone (mean = 5.00 ± 0.9815 g), diclofenac (mean = 2.50 ± 0.8337 g) and indomethacin (mean = 6.650 ± 4.069 g) or CB2 cannabinoid antagonist to dipyrone (mean = 1.050 ± 6.436 g), diclofenac (mean = 6.675 ± 1.368 g) and indomethacin (mean = 2.85 ± 5.01 g). Thus, cannabinoid receptors do not seem to be involved in the peripheral antinociceptive mechanism of the NSAIDs dipyrone, diclofenac and indomethacin.


Asunto(s)
Animales , Masculino , Antiinflamatorios no Esteroideos/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Nocicepción/efectos de los fármacos , Receptor Cannabinoide CB1/agonistas , /agonistas , Endocannabinoides/antagonistas & inhibidores , Endocannabinoides/farmacología , Dimensión del Dolor , Ratas Wistar , Receptor Cannabinoide CB1/fisiología , /fisiología
2.
West Indian med. j ; 61(3): 264-270, June 2012. ilus
Artículo en Inglés | LILACS | ID: lil-672898

RESUMEN

Cannabis sativa is one of the oldest herbal remedies known to man. Over the past four thousand years, it has been used for the treatment of numerous diseases but due to its psychoactive properties, its current medicinal usage is highly restricted. In this review, we seek to highlight advances made over the last forty years in the understanding of the mechanisms responsible for the effects of cannabis on the human body and how these can potentially be utilized in clinical practice. During this time, the primary active ingredients in cannabis have been isolated, specific cannabinoid receptors have been discovered and at least five endogenous cannabinoid neurotransmitters (endocannabinoids) have been identified. Together, these form the framework of a complex endocannabinoid signalling system that has widespread distribution in the body and plays a role in regulating numerous physiological processes within the body. Cannabinoid ligands are therefore thought to display considerable therapeutic potential and the drive to develop compounds that can be targeted to specific neuronal systems at low enough doses so as to eliminate cognitive side effects remains the 'holy grail' of endocannabinoid research.


La cannabis sativa es una especie herbácea usada en uno de los remedios herbarios más viejos conocidos al ser humano. Durante los últimos cuatro mil anos, se ha usado para el tratamiento de numerosas enfermedades, pero debido a sus propiedades psicoactivas, su uso medicinal actual se halla muy restringido. En este estudio, se busca resaltar los adelantos hechos durante los últimos cuarenta anos en cuanto a entender los mecanismos responsables de los efectos del cannabis sobre el cuerpo humano, y cómo éstos pueden utilizarse potencialmente en la práctica clínica. Durante este tiempo, se han aislado los ingredientes activos primarios en el cannabis, se han descubierto receptores canna-binoides específicos, y se han identificado por lo menos cinco neurotransmisores endógenos (endo-cannabinoides). Juntos, éstos forman la estructura de un complejo sistema de senalización endocannabinoide, el cual tiene una amplia distribución en el cuerpo y desempena un papel en la regulación de numerosos procesos fisiológicos dentro del organismo. Por tanto, se piensa que los ligandos cannabinoides despliegan un considerable potencial terapêutico. Así, el dinamismo para desarrollar compuestos que puedan ser dirigidos a sistemas neuronales en dosis suficientemente bajas como para eliminar los efectos cognitivos secundarios, sigue siendo el "santo grial" de la investigación de los endocannabinoides.


Asunto(s)
Animales , Humanos , Cannabinoides/uso terapéutico , Cannabis , Endocannabinoides/fisiología , Cannabinoides/farmacología , Endocannabinoides/farmacología , Endocannabinoides/uso terapéutico
3.
Braz. j. med. biol. res ; 45(4): 357-365, Apr. 2012. tab
Artículo en Inglés | LILACS | ID: lil-622757

RESUMEN

This paper presents an up-to-date review of the evidence indicating that atypical neurotransmitters such as nitric oxide (NO) and endocannabinoids (eCBs) play an important role in the regulation of aversive responses in the periaqueductal gray (PAG). Among the results supporting this role, several studies have shown that inhibitors of neuronal NO synthase or cannabinoid receptor type 1 (CB1) receptor agonists cause clear anxiolytic responses when injected into this region. The nitrergic and eCB systems can regulate the activity of classical neurotransmitters such as glutamate and γ-aminobutyric acid (GABA) that control PAG activity. We propose that they exert a ‘fine-tuning’ regulatory control of defensive responses in this area. This control, however, is probably complex, which may explain the usually bell-shaped dose-response curves observed with drugs that act on NO- or CB1-mediated neurotransmission. Even if the mechanisms responsible for this complex interaction are still poorly understood, they are beginning to be recognized. For example, activation of transient receptor potential vanilloid type-1 channel (TRPV1) receptors by anandamide seems to counteract the anxiolytic effects induced by CB1 receptor activation caused by this compound. Further studies, however, are needed to identify other mechanisms responsible for this fine-tuning effect.


Asunto(s)
Animales , Ratones , Ratas , Ansiedad/fisiopatología , Reacción de Fuga/fisiología , Neurotransmisores/fisiología , Sustancia Gris Periacueductal/fisiología , Transmisión Sináptica/fisiología , Ansiedad/metabolismo , Ácidos Araquidónicos/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Endocannabinoides/farmacología , Endocannabinoides/fisiología , Óxido Nítrico/fisiología , Sustancia Gris Periacueductal/metabolismo , Alcamidas Poliinsaturadas/farmacología , Canales Catiónicos TRPV/fisiología
4.
Journal of Veterinary Research. 2011; 66 (1): 31-34
en Persa | IMEMR | ID: emr-125125

RESUMEN

Endocannabinoid system play a critical role in the regulation of appetite in mammals. In the present study, the effect of avian brain CB[1] receptor on food intake of broilers was studied. ACEA, a potent CB[1] agonist, and AM28 1, a potent CB[1] antagonist, were injected into the chicken right lateral cerebral ventricle and food intake was measured 15, 30, 60, 120, and 180 minutes post injection. The results indicate that CB[1] agonist and antagonist increase and decrease food intake, respectively. Also, pre treatment with CB1 antagonistfully inhibits the CB[1]-agonist-induced food intake. The results of the study is consistent with the experiments carried out in mammals


Asunto(s)
Animales , Ingestión de Alimentos , Endocannabinoides/farmacología , Pollos
5.
Braz. j. med. biol. res ; 42(6): 556-560, June 2009. graf
Artículo en Inglés | LILACS | ID: lil-512761

RESUMEN

The endocannabinoid system is involved in the control of many physiological functions, including the control of emotional states. In rodents, previous exposure to an open field increases the anxiety-like behavior in the elevated plus-maze. Anxiolytic-like effects of pharmacological compounds that increase endocannabinoid levels have been well documented. However, these effects are more evident in animals with high anxiety levels. Several studies have described characteristic inverted U-shaped dose-response effects of drugs that modulate the endocannabinoid levels. However, there are no studies showing the effects of different doses of exogenous anandamide, an endocannabinoid, in animal models of anxiety. Thus, in the present study, we determined the dose-response effects of exogenous anandamide at doses of 0.01, 0.1, and 1.0 mg/kg in C57BL/6 mice (N = 10/group) sequentially submitted to the open field and elevated plus-maze. Anandamide was diluted in 0.9 percent saline, ethyl alcohol, Emulphor® (18:1:1) and administered ip (0.1 mL/10 g body weight); control animals received the same volume of anandamide vehicle. Anandamide at the dose of 0.1 mg/kg (but not of 0.01 or 1 mg/kg) increased (P < 0.05) the time spent and the distance covered in the central zone of the open field, as well as the exploration of the open arms of the elevated plus-maze. Thus, exogenous anandamide, like pharmacological compounds that increase endocannabinoid levels, promoted a characteristic inverted U-shaped dose-response effect in animal models of anxiety. Furthermore, anandamide (0.1 mg/kg) induced an anxiolytic-like effect in the elevated plus-maze (P < 0.05) after exposing the animals to the open field test.


Asunto(s)
Animales , Masculino , Ratones , Ansiolíticos/farmacología , Ansiedad/tratamiento farmacológico , Ácidos Araquidónicos/farmacología , Endocannabinoides/farmacología , Conducta Exploratoria/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Alcamidas Poliinsaturadas/farmacología , Relación Dosis-Respuesta a Droga , Ratones Endogámicos BALB C , Aprendizaje por Laberinto/efectos de los fármacos
6.
Braz. j. med. biol. res ; 42(6): 537-544, June 2009. ilus, tab, graf
Artículo en Inglés | LILACS | ID: lil-512770

RESUMEN

Our objective was to determine the effect of arachidonylethanolamide (anandamide, AEA) injected intracerebroventricularly (icv) into the lateral ventricle of the rat brain on submandibular gland (SMG) salivary secretion. Parasympathetic decentralization (PSD) produced by cutting the chorda tympani nerve strongly inhibited methacholine (MC)-induced salivary secretion while sympathetic denervation (SD) produced by removing the superior cervical ganglia reduced it slightly. Also, AEA (50 ng/5 µL, icv) significantly decreased MC-induced salivary secretion in intact rats (MC 1 µg/kg: control (C), 5.3 ± 0.6 vs AEA, 2.7 ± 0.6 mg; MC 3 µg/kg: C, 17.6 ± 1.0 vs AEA, 8.7 ± 0.9 mg; MC 10 µg/kg: C, 37.4 ± 1.2 vs AEA, 22.9 ± 2.6 mg). However, AEA did not alter the significantly reduced salivary secretion in rats with PSD, but decreased the slightly reduced salivary secretion in rats with SD (MC 1 µg/kg: C, 3.8 ± 0.8 vs AEA, 1.4 ± 0.6 mg; MC 3 µg/kg: C, 14.7 ± 2.4 vs AEA, 6.9 ± 1.2 mg; P < 0.05; MC 10 µg/kg: C, 39.5 ± 1.0 vs AEA, 22.3 ± 0.5 mg; P < 0.001). We showed that the inhibitory effect of AEA is mediated by cannabinoid type 1 CB1 receptors and involves GABAergic neurotransmission, since it was blocked by previous injection of the CB1 receptor antagonist AM251 (500 ng/5 µL, icv) or of the GABA A receptor antagonist, bicuculline (25 ng/5 µL, icv). Our results suggest that parasympathetic neurotransmission from the central nervous system to the SMG can be inhibited by endocannabinoid and GABAergic systems.


Asunto(s)
Animales , Masculino , Ratas , Ácidos Araquidónicos/farmacología , Endocannabinoides/farmacología , Ventrículos Laterales/efectos de los fármacos , Alcamidas Poliinsaturadas/farmacología , Saliva , Transmisión Sináptica/efectos de los fármacos , Ácidos Araquidónicos/administración & dosificación , Endocannabinoides/administración & dosificación , Inyecciones Intraventriculares , Alcamidas Poliinsaturadas/administración & dosificación , Ratas Wistar , Saliva/efectos de los fármacos , Glándula Submandibular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA